Effects of subcutaneous IL-2 therapy on telomere lengths in PBMC in HIV-infected patients

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Effects of subcutaneous IL-2 therapy on telomere lengths in PBMC in HIV-infected patients. / Aladdin, H; Larsen, C S; Schjerling, P; Møller, B K; Buhl, M R; Gerstoft, J; Pedersen, Bente Klarlund; Ullum, H.

In: Scandinavian Journal of Immunology, Vol. 53, No. 3, 03.2001, p. 315-9.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Aladdin, H, Larsen, CS, Schjerling, P, Møller, BK, Buhl, MR, Gerstoft, J, Pedersen, BK & Ullum, H 2001, 'Effects of subcutaneous IL-2 therapy on telomere lengths in PBMC in HIV-infected patients', Scandinavian Journal of Immunology, vol. 53, no. 3, pp. 315-9.

APA

Aladdin, H., Larsen, C. S., Schjerling, P., Møller, B. K., Buhl, M. R., Gerstoft, J., Pedersen, B. K., & Ullum, H. (2001). Effects of subcutaneous IL-2 therapy on telomere lengths in PBMC in HIV-infected patients. Scandinavian Journal of Immunology, 53(3), 315-9.

Vancouver

Aladdin H, Larsen CS, Schjerling P, Møller BK, Buhl MR, Gerstoft J et al. Effects of subcutaneous IL-2 therapy on telomere lengths in PBMC in HIV-infected patients. Scandinavian Journal of Immunology. 2001 Mar;53(3):315-9.

Author

Aladdin, H ; Larsen, C S ; Schjerling, P ; Møller, B K ; Buhl, M R ; Gerstoft, J ; Pedersen, Bente Klarlund ; Ullum, H. / Effects of subcutaneous IL-2 therapy on telomere lengths in PBMC in HIV-infected patients. In: Scandinavian Journal of Immunology. 2001 ; Vol. 53, No. 3. pp. 315-9.

Bibtex

@article{5ee77b4b63874446ba5111982e62d70b,
title = "Effects of subcutaneous IL-2 therapy on telomere lengths in PBMC in HIV-infected patients",
abstract = "In this study we investigated the effect of interleukin-2 (IL-2) on mean terminal restriction fragment (TRF) lengths in peripheral blood mononuclear cells (PBMC). Ten human immunodeficiency virus (HIV)-infected individuals were included and IL-2 was administered subcutaneously with 3 x 106 IU three times a week for 24 weeks. Mean TRF length was decreased on average by 267 bp at week 4 (P = 0.03) and 286 bp at week 8 (P = 0.09). Individual TRF changes at weeks 12, 16, 20 and 24 were highly variable. However, in the 12 weeks following therapy, TRF lengths generally increased reaching baseline levels by the end of the study. At baseline, mean TRF lengths were positively correlated to the ratio of na{\"i}ve and memory phenotype within both CD4+ and CD8+ cells. This study shows that IL-2 treatment induces transient shortened mean TRF lengths in PBMC from HIV-infected individuals, indicating that IL-2 enhances the lymphocyte count by peripheral proliferation or recruitment of memory T cells into the blood.",
keywords = "Adjuvants, Immunologic, Antiretroviral Therapy, Highly Active, CD4 Lymphocyte Count, CD4-Positive T-Lymphocytes, CD8-Positive T-Lymphocytes, Cell Division, HIV Infections, Humans, Immunologic Memory, Injections, Subcutaneous, Interleukin-2, Leukocytes, Mononuclear, Lymphocyte Activation, Telomere, Journal Article",
author = "H Aladdin and Larsen, {C S} and P Schjerling and M{\o}ller, {B K} and Buhl, {M R} and J Gerstoft and Pedersen, {Bente Klarlund} and H Ullum",
year = "2001",
month = mar,
language = "English",
volume = "53",
pages = "315--9",
journal = "Scandinavian Journal of Immunology, Supplement",
issn = "0301-6323",
publisher = "Wiley-Blackwell",
number = "3",

}

RIS

TY - JOUR

T1 - Effects of subcutaneous IL-2 therapy on telomere lengths in PBMC in HIV-infected patients

AU - Aladdin, H

AU - Larsen, C S

AU - Schjerling, P

AU - Møller, B K

AU - Buhl, M R

AU - Gerstoft, J

AU - Pedersen, Bente Klarlund

AU - Ullum, H

PY - 2001/3

Y1 - 2001/3

N2 - In this study we investigated the effect of interleukin-2 (IL-2) on mean terminal restriction fragment (TRF) lengths in peripheral blood mononuclear cells (PBMC). Ten human immunodeficiency virus (HIV)-infected individuals were included and IL-2 was administered subcutaneously with 3 x 106 IU three times a week for 24 weeks. Mean TRF length was decreased on average by 267 bp at week 4 (P = 0.03) and 286 bp at week 8 (P = 0.09). Individual TRF changes at weeks 12, 16, 20 and 24 were highly variable. However, in the 12 weeks following therapy, TRF lengths generally increased reaching baseline levels by the end of the study. At baseline, mean TRF lengths were positively correlated to the ratio of naïve and memory phenotype within both CD4+ and CD8+ cells. This study shows that IL-2 treatment induces transient shortened mean TRF lengths in PBMC from HIV-infected individuals, indicating that IL-2 enhances the lymphocyte count by peripheral proliferation or recruitment of memory T cells into the blood.

AB - In this study we investigated the effect of interleukin-2 (IL-2) on mean terminal restriction fragment (TRF) lengths in peripheral blood mononuclear cells (PBMC). Ten human immunodeficiency virus (HIV)-infected individuals were included and IL-2 was administered subcutaneously with 3 x 106 IU three times a week for 24 weeks. Mean TRF length was decreased on average by 267 bp at week 4 (P = 0.03) and 286 bp at week 8 (P = 0.09). Individual TRF changes at weeks 12, 16, 20 and 24 were highly variable. However, in the 12 weeks following therapy, TRF lengths generally increased reaching baseline levels by the end of the study. At baseline, mean TRF lengths were positively correlated to the ratio of naïve and memory phenotype within both CD4+ and CD8+ cells. This study shows that IL-2 treatment induces transient shortened mean TRF lengths in PBMC from HIV-infected individuals, indicating that IL-2 enhances the lymphocyte count by peripheral proliferation or recruitment of memory T cells into the blood.

KW - Adjuvants, Immunologic

KW - Antiretroviral Therapy, Highly Active

KW - CD4 Lymphocyte Count

KW - CD4-Positive T-Lymphocytes

KW - CD8-Positive T-Lymphocytes

KW - Cell Division

KW - HIV Infections

KW - Humans

KW - Immunologic Memory

KW - Injections, Subcutaneous

KW - Interleukin-2

KW - Leukocytes, Mononuclear

KW - Lymphocyte Activation

KW - Telomere

KW - Journal Article

M3 - Journal article

C2 - 11251891

VL - 53

SP - 315

EP - 319

JO - Scandinavian Journal of Immunology, Supplement

JF - Scandinavian Journal of Immunology, Supplement

SN - 0301-6323

IS - 3

ER -

ID: 180571584